AR122505A1 - Procesos para preparar un inhibidor de jak1 - Google Patents
Procesos para preparar un inhibidor de jak1Info
- Publication number
- AR122505A1 AR122505A1 ARP210101500A ARP210101500A AR122505A1 AR 122505 A1 AR122505 A1 AR 122505A1 AR P210101500 A ARP210101500 A AR P210101500A AR P210101500 A ARP210101500 A AR P210101500A AR 122505 A1 AR122505 A1 AR 122505A1
- Authority
- AR
- Argentina
- Prior art keywords
- prepare
- processes
- jak1 inhibitor
- compound
- jak1
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/26—Catalysts comprising hydrides, coordination complexes or organic compounds containing in addition, inorganic metal compounds not provided for in groups B01J31/02 - B01J31/24
- B01J31/28—Catalysts comprising hydrides, coordination complexes or organic compounds containing in addition, inorganic metal compounds not provided for in groups B01J31/02 - B01J31/24 of the platinum group metals, iron group metals or copper
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Reivindicación 1: Un proceso para preparar (base libre del Compuesto 1) o una sal de este, caracterizado porque comprende hacer reaccionar (Compuesto 1x) con (Compuesto 2x) para formar la base libre del Compuesto 1, o una sal de este.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063033618P | 2020-06-02 | 2020-06-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR122505A1 true AR122505A1 (es) | 2022-09-14 |
Family
ID=76601838
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP210101500A AR122505A1 (es) | 2020-06-02 | 2021-06-02 | Procesos para preparar un inhibidor de jak1 |
Country Status (18)
Country | Link |
---|---|
US (1) | US11685731B2 (es) |
EP (1) | EP4157831A1 (es) |
JP (1) | JP2023528868A (es) |
KR (1) | KR20230027086A (es) |
CN (1) | CN115836065A (es) |
AR (1) | AR122505A1 (es) |
AU (1) | AU2021283271A1 (es) |
BR (1) | BR112022024632A2 (es) |
CA (1) | CA3184275A1 (es) |
CL (1) | CL2022003363A1 (es) |
CO (1) | CO2022017344A2 (es) |
CR (1) | CR20220612A (es) |
EC (1) | ECSP22091930A (es) |
IL (1) | IL298118A (es) |
MX (1) | MX2022015221A (es) |
PE (1) | PE20231102A1 (es) |
TW (1) | TW202210471A (es) |
WO (1) | WO2021247668A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI3527263T1 (sl) | 2013-05-17 | 2021-05-31 | Incyte Corporation | Derivati bipirazola kot zaviralci JAK |
SG11202007805SA (en) | 2018-02-16 | 2020-09-29 | Incyte Corp | Jak1 pathway inhibitors for the treatment of cytokine-related disorders |
CA3204374A1 (en) | 2020-12-08 | 2022-06-16 | Incyte Corporation | Jak1 pathway inhibitors for the treatment of vitiligo |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
DE69942097D1 (de) | 1998-08-11 | 2010-04-15 | Novartis Ag | Isochinoline derivate mit angiogenesis-hemmender wirkung |
US6133031A (en) | 1999-08-19 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense inhibition of focal adhesion kinase expression |
GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
NZ522783A (en) | 2000-06-28 | 2004-07-30 | Smithkline Beecham P | Wet milling process for pharmaceuticals with agitator or chamber having nylon with internal lubricant |
DE60230890D1 (de) | 2001-09-19 | 2009-03-05 | Aventis Pharma Sa | Indolizine als kinaseproteinhemmer |
ATE335490T1 (de) | 2001-10-30 | 2006-09-15 | Novartis Pharma Gmbh | Staurosporin-derivate als hemmer der flt3- rezeptor-tyrosinkinase-wirkung |
PE20040522A1 (es) | 2002-05-29 | 2004-09-28 | Novartis Ag | Derivados de diarilurea dependientes de la cinasa de proteina |
GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
TWI335913B (en) | 2002-11-15 | 2011-01-11 | Vertex Pharma | Diaminotriazoles useful as inhibitors of protein kinases |
UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
AR045944A1 (es) | 2003-09-24 | 2005-11-16 | Novartis Ag | Derivados de isoquinolina 1.4-disustituidas |
JP2008520612A (ja) | 2004-11-24 | 2008-06-19 | ノバルティス アクチエンゲゼルシャフト | JAK阻害剤およびBcr−Abl、Flt−3、FAKまたはRAFキナーゼ阻害剤のうち少なくとも1個の組合せ |
DK2348023T5 (da) | 2005-12-13 | 2017-05-15 | Incyte Holdings Corp | Heteroaryl-substituerede pyrrolo[2,3-b]pyridiner og pyrrolo[2,3-b]pyrimidiner som Janus-kinase-inhibitorer |
RS53245B2 (sr) | 2007-06-13 | 2022-10-31 | Incyte Holdings Corp | Soli inhibitora janus kinaze (r)-3-(4-(7h-pirolo(2,3-d) pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopentilpropan-nitrila |
CL2008001709A1 (es) | 2007-06-13 | 2008-11-03 | Incyte Corp | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. |
BRPI0820544A2 (pt) | 2007-11-16 | 2015-06-16 | Incyte Corp | 4-pirazolil-n-arilpirimidin-2-aminas e pirazolil-n-heteroarilpirimidin-2-aminas como inibidores de janus cinase |
DK2288610T3 (en) | 2008-03-11 | 2016-11-28 | Incyte Holdings Corp | Azetidinesulfonic AND CYCLOBUTANDERIVATER AS JAK INHIBITORS |
CL2009001884A1 (es) | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. |
JOP20190231A1 (ar) | 2009-01-15 | 2017-06-16 | Incyte Corp | طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به |
EP2432472B1 (en) | 2009-05-22 | 2019-10-02 | Incyte Holdings Corporation | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors |
AU2010249380B2 (en) | 2009-05-22 | 2015-08-20 | Incyte Holdings Corporation | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as Janus kinase inhibitors |
US9249145B2 (en) | 2009-09-01 | 2016-02-02 | Incyte Holdings Corporation | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
KR101805936B1 (ko) | 2009-10-09 | 2017-12-07 | 인사이트 홀딩스 코포레이션 | 3-(4-(7H-피롤로〔2,3-d〕피리미딘-4-일)-1H-피라졸-1-일)-3-사이클로펜틸프로판니트릴의 하이드록실, 케토 및 글루쿠로나이드 유도체 |
EP2536729A1 (en) | 2010-02-18 | 2012-12-26 | Incyte Corporation | Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors |
SI3354652T1 (sl) | 2010-03-10 | 2020-08-31 | Incyte Holdings Corporation | Derivati piperidin-4-il azetidina kot inhibitorji JAK1 |
CA2796388A1 (en) | 2010-04-14 | 2011-10-20 | Array Biopharma Inc. | 5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of jak kinases |
MY178634A (en) | 2010-05-21 | 2020-10-19 | Incyte Corp | Topical formulation for a jak inhibitor |
JP5917545B2 (ja) | 2010-11-19 | 2016-05-18 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Jak阻害剤としてのシクロブチル置換ピロロピリジンおよびピロロピリミジン誘導体 |
US9034884B2 (en) | 2010-11-19 | 2015-05-19 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors |
ES2545110T3 (es) | 2010-12-10 | 2015-09-08 | Rottapharm Biotech S.R.L. | Derivados de piridinamida como antagonistas del receptor EP4 |
SG192910A1 (en) | 2011-02-24 | 2013-09-30 | Massachusetts Inst Technology | ALTERNATIVELY SPLICED mRNA ISOFORMS AS PROGNOSTIC INDICATORS FOR METASTATIC CANCER |
EA201490042A1 (ru) | 2011-06-20 | 2014-10-30 | Инсайт Корпорейшн | Азетидинил-фенил-, пиридил- или пиразинилкарбоксамидные производные как ингибиторы jak |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
WO2013043962A1 (en) | 2011-09-22 | 2013-03-28 | Merck Sharp & Dohme Corp. | Cyanomethylpyrazole carboxamides as janus kinase inhibitors |
AR091079A1 (es) | 2012-05-18 | 2014-12-30 | Incyte Corp | Derivados de pirrolopirimidina y pirrolopiridina sustituida con piperidinilciclobutilo como inhibidores de jak |
KR20150074193A (ko) | 2012-11-01 | 2015-07-01 | 인사이트 코포레이션 | Jak 억제제로서 트리사이클릭 융합된 티오펜 유도체 |
WO2014078486A1 (en) | 2012-11-15 | 2014-05-22 | Incyte Corporation | Sustained-release dosage forms of ruxolitinib |
KR102366356B1 (ko) | 2013-03-06 | 2022-02-23 | 인사이트 홀딩스 코포레이션 | Jak 저해제를 제조하기 위한 방법 및 중간생성물 |
JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
US9371282B2 (en) | 2013-05-17 | 2016-06-21 | Centrexion Therapeutics Corporation | Somatostatin receptor subtype 4 (SSTR4) agonists |
EA201592126A1 (ru) | 2013-05-17 | 2016-05-31 | Ф. Хоффманн-Ля Рош Аг | 6-мостиковые гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b |
EP2803668A1 (en) | 2013-05-17 | 2014-11-19 | Boehringer Ingelheim International Gmbh | Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles |
SI3527263T1 (sl) | 2013-05-17 | 2021-05-31 | Incyte Corporation | Derivati bipirazola kot zaviralci JAK |
PE20220579A1 (es) | 2013-08-07 | 2022-04-20 | Incyte Corp | Formas de dosificacion de liberacion prolongada para un inhibidor de jak 1 |
CN112494652A (zh) | 2014-02-28 | 2021-03-16 | 因赛特公司 | 用于治疗骨髓增生异常综合征的jak1抑制剂 |
KR20170007331A (ko) | 2014-04-30 | 2017-01-18 | 인사이트 코포레이션 | Jak1 억제제의 제조 방법 및 이에 대한 신규한 형태 |
WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
LT3233843T (lt) | 2014-12-16 | 2019-12-10 | Novartis Ag | Izoksazolo hidroksamido rūgšties junginiai, kaip lpxc inhibitoriai |
-
2021
- 2021-06-02 AU AU2021283271A patent/AU2021283271A1/en active Pending
- 2021-06-02 EP EP21734728.5A patent/EP4157831A1/en active Pending
- 2021-06-02 WO PCT/US2021/035400 patent/WO2021247668A1/en unknown
- 2021-06-02 CN CN202180048817.4A patent/CN115836065A/zh active Pending
- 2021-06-02 CA CA3184275A patent/CA3184275A1/en active Pending
- 2021-06-02 KR KR1020227045757A patent/KR20230027086A/ko unknown
- 2021-06-02 MX MX2022015221A patent/MX2022015221A/es unknown
- 2021-06-02 CR CR20220612A patent/CR20220612A/es unknown
- 2021-06-02 IL IL298118A patent/IL298118A/en unknown
- 2021-06-02 TW TW110119976A patent/TW202210471A/zh unknown
- 2021-06-02 PE PE2022002824A patent/PE20231102A1/es unknown
- 2021-06-02 JP JP2022574313A patent/JP2023528868A/ja active Pending
- 2021-06-02 AR ARP210101500A patent/AR122505A1/es unknown
- 2021-06-02 BR BR112022024632A patent/BR112022024632A2/pt unknown
- 2021-06-02 US US17/337,065 patent/US11685731B2/en active Active
-
2022
- 2022-11-29 CL CL2022003363A patent/CL2022003363A1/es unknown
- 2022-12-01 CO CONC2022/0017344A patent/CO2022017344A2/es unknown
- 2022-12-01 EC ECSENADI202291930A patent/ECSP22091930A/es unknown
Also Published As
Publication number | Publication date |
---|---|
IL298118A (en) | 2023-01-01 |
KR20230027086A (ko) | 2023-02-27 |
CR20220612A (es) | 2023-04-11 |
MX2022015221A (es) | 2023-03-08 |
CN115836065A (zh) | 2023-03-21 |
ECSP22091930A (es) | 2023-02-28 |
JP2023528868A (ja) | 2023-07-06 |
CL2022003363A1 (es) | 2023-05-19 |
AU2021283271A1 (en) | 2022-12-15 |
WO2021247668A1 (en) | 2021-12-09 |
US20210380563A1 (en) | 2021-12-09 |
EP4157831A1 (en) | 2023-04-05 |
BR112022024632A2 (pt) | 2023-02-28 |
PE20231102A1 (es) | 2023-07-19 |
CO2022017344A2 (es) | 2023-03-07 |
CA3184275A1 (en) | 2021-12-09 |
US11685731B2 (en) | 2023-06-27 |
TW202210471A (zh) | 2022-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR122505A1 (es) | Procesos para preparar un inhibidor de jak1 | |
CO2022002637A2 (es) | Proceso de fabricación de moduladores de cftr | |
UY39002A (es) | Inhibidores de egfr | |
CL2020000407A1 (es) | Proceso para preparar compuesto inhibidor de bet. (solicitud divisional 201803702). | |
AR118707A1 (es) | Inhibidores de la proteasa del vih | |
AR111960A1 (es) | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación | |
CO2020014586A2 (es) | Compuestos | |
EA202193015A1 (ru) | Ингибиторы cdk | |
CY1126067T1 (el) | Συντηγμενες πυρρολινες που δρουν σαν ειδικοι για ουβικιτινη αναστολεις πρωτεασης 30 (usp30) | |
ECSP23019419A (es) | Proceso e intermedios para preparar un inhibidor de jak1 | |
CR20220251A (es) | Nuevos derivados de metilquinazolinona | |
CO2018007008A2 (es) | "procesos mejorados para la preparación de osimertinib (azd9291) o una sal del mismo y "azd9291 anilina" o una sal del mismo" | |
CL2021002309A1 (es) | Compuestos útiles en la terapia del vih | |
MY198004A (en) | Antitumoral compounds | |
AR116951A1 (es) | Sales cristalinas de un inhibidor de calicreína plasmática | |
CO2023003281A2 (es) | Proceso e intermediarios para preparar un inhibidor de jak | |
MX2020011671A (es) | Nuevo proceso para la preparacion de diamidas antranilicas. | |
MX2023000970A (es) | Metodo de preparacion de aminofuranos. | |
UY39832A (es) | Inhibidores de cdk2 | |
AR107163A1 (es) | Inhibidores de quinasa | |
WO2020128020A3 (de) | Verfahren zur herstellung von 2-alkoxy-4-amino-5-methyl-pyridinen und/oder von 2-alkoxy-4-alkylamino-5-methyl-pyridinen | |
CO2022008127A2 (es) | Procesos e intermediario para la preparación de oxetan-2-ilmetanamina | |
MX2023006157A (es) | Mediadores lipidicos proresolutivos especializados para el tratamiento del pcos. | |
AR117014A1 (es) | Proceso para la síntesis de lactamas | |
MX2021013726A (es) | Butirato alimentario y sus usos. |